Vergelijking
Cagrilintide vs. Survodutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
1415456-99-3
2179963-22-7
Molecuulmassa
4253.7 g/mol
4727 g/mol
Halfwaardetijd
168 h
168 h
Sequentie
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteWerkingsmechanisme
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
4
waarvan bij mensen
3
4
Geregistreerde effecten
3
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Cagrilintide and Survodutide?
- Cagrilintide is classified as "Metabool", while Survodutide is classified as "Metabool". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Survodutide?
- The highest available evidence level is "Humane RCT" for Cagrilintide and "Humane RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Survodutide in Germany and the United States?
- Duitsland: Cagrilintide — Niet goedgekeurd, Survodutide — Niet goedgekeurd. Verenigde Staten: Cagrilintide — Niet goedgekeurd, Survodutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.